By
AmyT on
January 31, 2011
Speaking of iPhone-ish diabetes devices (aren’t we always?), a number of readers asked us lately for an update on the new Tandem insulin pump, which could hardly look more Apple’esque if it tried:
The San Diego-based company has been developing this one for several years, and recently added some famous names to its Clinical Advisory Board: insulin pump experts Dr. Bruce Bode, CDEs Virginia Valentine and John Walsch, and Dr. Steven Edelman of TCOYD fame.…
Read more »
By
AmyT on
December 21, 2010
Dr. Josh Makower is Co-founder of Stanford’s Biodesign Innovation Program, and a Consulting Associate Professor of Medicine at the Stanford University Medical School. He’s also Founder and Chief Executive Officer of ExploraMed, a medical device incubator. And he’s a Venture Partner with New Enterprise Associates, where he supports the investing activity in new medical devices.
In short, Dr. Makower is a world authority on med-tech innovation. I bumped into him while beginning preparations for the…
Read more »
By
AmyT on
November 16, 2010
Last Wednesday, diabetes researchers and advocates from around the country convened in Washington, DC, for an FDA hearing on the Artificial Pancreas with the aim of making this pipe dream a reality. The point of the hearing was to allow JDRF and other stakeholders — researchers, industry reps, and patients — a chance to provide input on the Artificial Pancreas Project, in particular “recommendations to ensure the safe and effective testing of artificial pancreas technology…
Read more »
The relative accuracy of blood glucose meters has of course been in the spotlight of late, since the FDA held a hearing to “crack down” on this issue last Fall. Funny, but I always assumed this had more to do with the technology inside the meter than the test strips themselves. Silly me.
One of this year’s buzzwords at the ADA Conference in Orlando last week was the “PQQ Enzyme” {glucose dehydrogenase (GDH)-pyrroloquino-linequinone (PQQ)} –…
Read more »
By
AmyT on
March 24, 2010
More details on the recent FDA Hearings on the accuracy of blood glucose monitoring devices: I was surprised by the report from patient advocate Ellen Ullman on Monday, noting that patient interests seem to be grossly underrepresented, and lots of experts seem to believe that the status quo of +/- 20% error margin is all that any of us need (or can handle). Grrrrr….
See Dear FDA over at “Your Diabetes May Vary” for an…
Read more »
